Deirdre Weymann

1.1k total citations
34 papers, 561 citations indexed

About

Deirdre Weymann is a scholar working on Economics and Econometrics, Genetics and Cancer Research. According to data from OpenAlex, Deirdre Weymann has authored 34 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 11 papers in Genetics and 8 papers in Cancer Research. Recurrent topics in Deirdre Weymann's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Genomics and Rare Diseases (10 papers) and Cancer Genomics and Diagnostics (8 papers). Deirdre Weymann is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Genomics and Rare Diseases (10 papers) and Cancer Genomics and Diagnostics (8 papers). Deirdre Weymann collaborates with scholars based in Canada, United Kingdom and Australia. Deirdre Weymann's co-authors include Dean A. Regier, Steven G. Morgan, Emilie J. Gladstone, Kate Smolina, Samantha Pollard, Jeffrey Proulx, Cara Tannenbaum, John D. Rioux, James Buchanan and Sarah Wordsworth and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Deirdre Weymann

32 papers receiving 550 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deirdre Weymann Canada 13 226 155 122 76 75 34 561
Jan Peter Kösters Denmark 6 340 1.5× 60 0.4× 57 0.5× 30 0.4× 43 0.6× 7 628
Gisbert Selke Germany 10 202 0.9× 27 0.2× 32 0.3× 95 1.3× 19 0.3× 20 765
Rahul Shenolikar United States 13 98 0.4× 64 0.4× 17 0.1× 26 0.3× 47 0.6× 47 531
Karen Van Nuys United States 10 128 0.6× 19 0.1× 55 0.5× 12 0.2× 45 0.6× 24 590
Cara L. McDermott United States 15 119 0.5× 32 0.2× 42 0.3× 21 0.3× 182 2.4× 51 586
Julie Sakowski United States 13 142 0.6× 42 0.3× 48 0.4× 17 0.2× 48 0.6× 18 446
Sunita Miles United States 5 98 0.4× 29 0.2× 185 1.5× 187 2.5× 100 1.3× 7 768
Monica Fujii United States 10 46 0.2× 14 0.1× 99 0.8× 106 1.4× 107 1.4× 28 561
Jyotsna Mehta United States 11 277 1.2× 34 0.2× 22 0.2× 9 0.1× 67 0.9× 25 712
Kathryn Teng United States 10 42 0.2× 23 0.1× 94 0.8× 18 0.2× 71 0.9× 25 336

Countries citing papers authored by Deirdre Weymann

Since Specialization
Citations

This map shows the geographic impact of Deirdre Weymann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deirdre Weymann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deirdre Weymann more than expected).

Fields of papers citing papers by Deirdre Weymann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deirdre Weymann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deirdre Weymann. The network helps show where Deirdre Weymann may publish in the future.

Co-authorship network of co-authors of Deirdre Weymann

This figure shows the co-authorship network connecting the top 25 collaborators of Deirdre Weymann. A scholar is included among the top collaborators of Deirdre Weymann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deirdre Weymann. Deirdre Weymann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krebs, Emanuel, Deirdre Weymann, Cheryl Ho, et al.. (2025). Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation. JCO Precision Oncology. 9(9). e2400631–e2400631. 1 indexed citations
2.
Krebs, Emanuel, Deirdre Weymann, Tania Bubela, & Dean A. Regier. (2025). How life-cycle real-world evidence can bridge evidentiary gaps in precision oncology. Frontiers in Medicine. 12. 1563950–1563950.
3.
Weymann, Deirdre, John Buckell, Samantha Pollard, et al.. (2024). Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada. JAMA Network Open. 7(7). e2420842–e2420842. 2 indexed citations
4.
Marshall, Deborah A., James Buchanan, Kurt D. Christensen, et al.. (2024). Paving the path for implementation of clinical genomic sequencing globally: Are we ready?. Health Affairs Scholar. 2(5). qxae053–qxae053. 5 indexed citations
5.
Pollard, Samantha, Deirdre Weymann, Emanuel Krebs, et al.. (2024). “I Just Assumed This Was Already Being Done”: Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology. JCO Precision Oncology. 8(8). e2400184–e2400184. 1 indexed citations
6.
Regier, Dean A., Brandon Chan, Samantha Pollard, et al.. (2024). Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: Evidence from Canada. Genetics in Medicine. 26(4). 101069–101069. 9 indexed citations
7.
Pataky, Reka, Deirdre Weymann, Ian Bosdet, et al.. (2024). Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer. Journal of Cancer Policy. 41. 100496–100496. 2 indexed citations
8.
Weymann, Deirdre, et al.. (2023). Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions. Value in Health. 26(11). 1608–1617. 9 indexed citations
9.
10.
Weymann, Deirdre, Brandon Chan, & Dean A. Regier. (2023). Genetic matching for time-dependent treatments: a longitudinal extension and simulation study. BMC Medical Research Methodology. 23(1). 181–181. 1 indexed citations
11.
Pollard, Samantha, Deirdre Weymann, Sarah Wordsworth, et al.. (2022). Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health. 25(8). 1371–1380. 11 indexed citations
12.
Regier, Dean A., Samantha Pollard, Tania Bubela, et al.. (2022). A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. npj Precision Oncology. 6(1). 76–76. 26 indexed citations
13.
Pollard, Samantha, Deirdre Weymann, Jessica L. Dunne, et al.. (2021). Toward the diagnosis of rare childhood genetic diseases: what do parents value most?. European Journal of Human Genetics. 29(10). 1491–1501. 29 indexed citations
14.
Weymann, Deirdre, Nick Dragojlovic, Samantha Pollard, & Dean A. Regier. (2019). Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges. Journal of Community Genetics. 13(5). 467–476. 22 indexed citations
15.
Weymann, Deirdre, Emilie J. Gladstone, Kate Smolina, & Steven G. Morgan. (2017). Long-term sedative use among community-dwelling adults: a population-based analysis. CMAJ Open. 5(1). E52–E60. 22 indexed citations
16.
Morgan, Steven G. & Deirdre Weymann. (2017). Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada. European Journal of Clinical Pharmacology. 73(8). 1001–1008. 7 indexed citations
17.
Morgan, Steven G., Emilie J. Gladstone, Deirdre Weymann, & Nadia Khan. (2017). The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study. CMAJ Open. 5(1). E198–E204. 4 indexed citations
18.
Rioux, John D., et al.. (2016). Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ Open. 4(2). E346–E351. 93 indexed citations
19.
Morgan, Steven G., Deirdre Weymann, Kate Smolina, et al.. (2016). Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. Age and Ageing. 45(4). 535–542. 65 indexed citations
20.
Renwick, Matthew J, Kate Smolina, Emilie J. Gladstone, Deirdre Weymann, & Steven G. Morgan. (2015). Postmarket policy considerations for biosimilar oncology drugs. The Lancet Oncology. 17(1). e31–e38. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Peter Kösters Breakdown of academic impact, for papers by Gisbert Selke Breakdown of academic impact, for papers by Rahul Shenolikar Breakdown of academic impact, for papers by Karen Van Nuys Breakdown of academic impact, for papers by Cara L. McDermott Breakdown of academic impact, for papers by Julie Sakowski Breakdown of academic impact, for papers by Sunita Miles Breakdown of academic impact, for papers by Monica Fujii Breakdown of academic impact, for papers by Jyotsna Mehta Breakdown of academic impact, for papers by Kathryn Teng
Rankless by CCL
2026